Wegovy Pill

Oral semaglutide has been launched in the US under the name “Wegovy Pill.” Oral semaglutide is the underlying drug name; it is the same active medicine used in injectable Wegovy.

Injectable and tablet forms are both GLP-1 receptor agonists, but the pill is taken as a daily tablet. It works on appetite regulation pathways to help reduce hunger and support lower calorie intake, alongside diet and physical activity.

We have no confirmation that the tablet will use the same name in the UK, and it has not yet received an MHRA licence. Its arrival is welcomed because it increases the choice available to clinicians and patients treating obesity.

For more on swallowing, timing with food, and adherence, read How Wegovy Pill works.

We already know that semaglutide works. Injectable Wegovy has been studied for many years in large international trials, consistently showing meaningful and sustained weight loss when combined with diet and lifestyle support. In clinical practice, many people respond well.

The key question for the tablet was whether the same medicine still works when taken by mouth. US clinical trials were designed to answer that.

The evidence behind the US approval

The Wegovy pill was approved by the US Food and Drug Administration based primarily on a large Phase 3 study called OASIS 4. See wegovy.com and drugs.com for manufacturer and professional drug information (US context).

OASIS 4 studied adults with obesity or overweight (with at least one weight-related health condition) who took oral semaglutide 25 mg once daily or placebo, alongside lifestyle support, for 64 weeks.

What the trial showed

In OASIS 4, people taking the Wegovy pill achieved substantial weight loss:

• Average weight loss of around 14% in the main analysis
• Up to 16–17% weight loss in people who were able to stay on treatment as planned
• Weight loss at a similar scale to that seen with injectable Wegovy 2.4 mg in comparable programmes

The pattern of side effects was consistent with what is already known for semaglutide, with digestive symptoms being the most common. These findings support the view that the tablet delivers the same proven medicine effectively, rather than being a weaker or compromise option.

Wegovy pill at a glance (US trial data)

Sources for trial summaries (US): wegovy.com, drugs.com.

What this means in practice

The clinical trial data supporting the Wegovy pill show that it uses the same active medicine as injectable Wegovy, that weight loss outcomes can be clinically meaningful and sustained, and that the tablet is a genuine alternative route for a proven treatment, not a second-best option by default.

UK regulatory note

Oral semaglutide is approved and available in the United States. It is not yet licensed for use in the UK, and UK prescribing guidance may differ once regulatory review is complete.

The Wegovy pill is taken once daily, usually in the morning on an empty stomach, to give the medicine a window to be absorbed. It should be swallowed whole with plain water and not crushed or chewed. A small glass is enough; too much water can interfere with absorption.

You are usually advised to wait about 30 minutes before eating, drinking anything else, or taking other oral medicines. Absorption can improve if you wait longer, but studies suggest 30 minutes is a practical balance; waiting longer is not a problem if that fits your routine.

In summary

• Take it on an empty stomach
• Swallow it whole with a small glass of plain water
• Avoid food, drinks, or other tablets for about 30 minutes afterwards
• Try to take it daily and not miss doses

Always follow your prescriber’s instructions and the patient information leaflet. If you have concerns, contact your prescriber.

Missing or forgetting doses happens. You should not intentionally skip doses to make medication last longer. There is a sound pharmacological reason: medicines taken daily are designed to maintain drug levels over about 24 hours.

What is pharmacokinetics?

Pharmacokinetics is the study of how a drug is absorbed, metabolised, and cleared by the body, and how drug levels change over time.

Put simply, when you take a medicine it goes through four main steps: getting in, moving around, being changed, and leaving your body. The time taken to leave your body matters for dosing because, after a certain point, levels may fall so low that the medicine no longer has a useful effect.

Something meant to be taken daily is unlikely to help you for longer than that dosing interval, so always try to take it as prescribed. If a dose is missed by accident, do not double the next dose unless your prescriber tells you to. Once the product is licensed in the UK, the manufacturer’s patient information leaflet will give direct guidance; if you are unsure, speak to your prescriber.

If several doses in a row are missed, you may need to restart at a lower dose, because the drug has left your system and your body may need to readjust — especially at higher strengths. Never self-adjust dosing. Prescription-only medicines have dose guidance that should not be changed without a clinical discussion.

Both contain semaglutide for weight management when clinically appropriate, but formulation and dosing differ: the injection is weekly; the tablet is daily with specific empty-stomach rules.

In US trial data (OASIS 4), oral semaglutide 25 mg daily produced weight loss in a similar range to that seen with injectable Wegovy 2.4 mg in major weight-loss trials — context and populations differ between studies, but the headline is that the tablet is a serious formulation of the same medicine, not a diluted alternative.

Switching between formulations always requires a new clinical assessment. For pen-based treatment, see the Wegovy injection hub.

We combine prescribing with practical guidance on nutrition and activity. Ask your clinician for resources that fit your plan.

For consultations, delivery, tracking, and GP communication, see the service FAQ.